Experience
Alto Neuroscience Announces $147.9 Million IPO
February 6, 2024
Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.
Related contacts
Related Practices & Industries
Carmot Therapeutics Enters Definitive Merger Agreement With Roche
December 3, 2023
Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement in which Roche will acquire Carmot.
Related contacts
Related Practices & Industries
Alto Neuroscience Closes Oversubscribed Series C
November 21, 2023
Cooley advised Alto Neuroscience, a company pioneering precision psychiatry by developing targeted medicines designed to help patients get better faster, on its oversubscribed $45 million Series C financing round.
Related contacts
Related Practices & Industries
Sprout Social Acquires Tagger Media
August 4, 2023
Cooley advised Sprout Social, a social media management software company, on its $140 million acquisition of Tagger Media, a top influencer marketing platform, and a concurrent $100 million secured debt facility, which will be partially used to fund the acquisition.
Related contacts
Related Practices & Industries
Cooley Advises on MindMed’s Successful Proxy Contest
June 21, 2023
Cooley advised MindMed, a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, on its successful proxy contest against FCM MM Holdings.
Related contacts
Related Practices & Industries
Related news and events
Admissions & credentials
California